Covered recipient · General Payments record
JOHN OLIVETI
General Payments · PY2018–2024
$3,198.20
- Reported across 138 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $384.40 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $211.33 | 11 |
| Acerta Pharma LLC | $118.99 | 1 |
| Amgen Inc. | $54.08 | 4 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $13.74 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111665638 | CMS |
| Amgen Inc. | $14.34 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111665640 | CMS |
| Amgen Inc. | $13.50 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111665642 | CMS |
| Amgen Inc. | $12.50 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111665644 | CMS |
| AstraZeneca Pharmaceuticals LP | $118.99 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110543791 | CMS |
| GlaxoSmithKline, LLC. | $5.82 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116618157 | CMS |
| GlaxoSmithKline, LLC. | $7.77 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116097846 | CMS |
| GlaxoSmithKline, LLC. | $19.64 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116435005 | CMS |
| GlaxoSmithKline, LLC. | $21.94 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116521366 | CMS |
| GlaxoSmithKline, LLC. | $22.14 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116552619 | CMS |
| GlaxoSmithKline, LLC. | $28.47 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116577370 | CMS |
| GlaxoSmithKline, LLC. | $23.67 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116337935 | CMS |
| GlaxoSmithKline, LLC. | $23.66 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116488295 | CMS |
| GlaxoSmithKline, LLC. | $18.68 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116525104 | CMS |
| GlaxoSmithKline, LLC. | $22.12 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116262135 | CMS |
| GlaxoSmithKline, LLC. | $17.42 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116246792 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.